Player FM - Internet Radio Done Right
Checked 2+ y ago
추가했습니다 eight 년 전
cancerGRACE - H. Jack West, MD, CancerGRACE - H. Jack West, and MD에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 cancerGRACE - H. Jack West, MD, CancerGRACE - H. Jack West, and MD 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Player FM -팟 캐스트 앱
Player FM 앱으로 오프라인으로 전환하세요!
Player FM 앱으로 오프라인으로 전환하세요!
Does Adding Avastin to Tarceva Help EGFR Positive Lung Cancer Patients?
Manage episode 318237857 series 1082357
cancerGRACE - H. Jack West, MD, CancerGRACE - H. Jack West, and MD에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 cancerGRACE - H. Jack West, MD, CancerGRACE - H. Jack West, and MD 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Drs. Nasser Hanna, Melissa Johnson and Jack West discuss results of a phase 2 trial presented at ASCO 2014 that studied if adding Avastin (bevicizumab) to Tarceva helped EGFR positive lung cancer patients increase progression-free survival. June 2014.
307 에피소드
Manage episode 318237857 series 1082357
cancerGRACE - H. Jack West, MD, CancerGRACE - H. Jack West, and MD에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 cancerGRACE - H. Jack West, MD, CancerGRACE - H. Jack West, and MD 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Drs. Nasser Hanna, Melissa Johnson and Jack West discuss results of a phase 2 trial presented at ASCO 2014 that studied if adding Avastin (bevicizumab) to Tarceva helped EGFR positive lung cancer patients increase progression-free survival. June 2014.
307 에피소드
모든 에피소드
×1 Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy? 4:36
4:36
나중에 재생
나중에 재생
리스트
좋아요
좋아요
4:36Dr. Nasser Hanna outlines the possible benefits of consolidation chest radiation for small cell lung cancer patients who respond well to chemotherapy.
What puts you at risk for inherited kidney cancer? Dr. Nizar Tannir discusses the signs doctors look for to determine if a kidney cancer patient should be screened for a familial syndrome.
1 Should All Small Cell Lung Cancer Patients Receive Prophylactic Cranial Irradiation? 5:28
5:28
나중에 재생
나중에 재생
리스트
좋아요
좋아요
5:28The doctors discuss the circumstances under which small cell lung cancer patients should receive prophylactic cranial irradiation.
NanoString Technology may help doctors learn what is driving tumor growth in kidney cancer patients and, therefore, determine what treatments may be most effective for them.
1 Is Necitumumab An Effective Antibody Against EGFR for Patients with Squamous Lung Cancer? 2:27
2:27
나중에 재생
나중에 재생
리스트
좋아요
좋아요
2:27Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.
1 How is the Heng Criteria Applied to Kidney Cancer Patients? 4:40
4:40
나중에 재생
나중에 재생
리스트
좋아요
좋아요
4:40Dr. Daniel Heng is the namesake of the Heng Criteria, which evaluates various factors of kidney cancer patients to determine their prognoses.
1 Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment? 7:28
7:28
나중에 재생
나중에 재생
리스트
좋아요
좋아요
7:28The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.
Dr. Lauren Harshman explains what PD1 (an immune T-cell) and PDL1 (a protein on the PD1 T-cell) are and how new drugs impact them to fight kidney cancer.
The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potential side effects and the ability of Zykadia to impact brain metastases.
Drugs in early stage clinical trials seem to show benefit for non-clear cell kidney cancer, but more trials must take place and patients are desperately needed to enroll in them.
1 What Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer 3:52
3:52
나중에 재생
나중에 재생
리스트
좋아요
좋아요
3:52"Dead negative," is how Dr. Nasser Hanna describes results of a phase 3 study that examined how patients with high MET expression did on the drug MetMab (onartuzumab).
Dr. Guru Sonpavde discusses what he does when he first begins treating a patient recently diagnosed with late stage kidney cancer.
Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positive patients.
Patients are responding very well to the next generation of immunotherapy drugs currently in clinical trials to treat kidney cancer.
1 CO1686 - 3rd Generation Drug for Acquired Resistance in EGFR Lung Cancer 4:10
4:10
나중에 재생
나중에 재생
리스트
좋아요
좋아요
4:10Lung cancer patients with the EGFR mutation who had progressed on other drugs did well on a new drug in clinical trial, though one particular side effect concerns some.
플레이어 FM에 오신것을 환영합니다!
플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.